Related Experiment Video
Updated: Feb 17, 2026
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
Purpose Of Review:
Low-grade gliomas present vexing management issues for neuro-oncologists. The relatively long survival compared to other brain tumors makes consideration of treatment toxicity, and thus timing of potentially damaging interventions such as surgery, radiation, and chemotherapy, crucial. Moreover, the rarity of these tumors makes clinical trials to ascertain optimal care challenging.
Recent Findings:
The discovery that most low-grade gliomas harbor isocitrate dehydrogenase (IDH) mutations that confer a favorable prognosis has improved diagnosis and risk stratification of these tumors. Although Level 1 evidence is still lacking, increasing data support the concept of maximal safe tumor debulking as a first step in tumor management. Preliminary results from a large randomized trial suggest chemotherapy is of comparable effectiveness to radiation therapy for one molecular subtype of low-grade glioma. Importantly, however, the final results of a phase 3 trial comparing radiation with or without procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy indicate a large survival advantage to combined chemotherapy and radiation, raising questions about using chemotherapy alone as an initial treatment strategy.
Summary:
While the combination of radiation and PCV provides the best proven overall survival with low-grade gliomas, important questions remain. These include whether the better-tolerated temozolomide is as effective as PCV in conjunction with radiation therapy and whether the use of initial chemotherapy as a strategy to defer the potential delayed cognitive toxicity associated with radiation will yield acceptable survival results with a favorable toxicity profile.
Insights
Optimal low-grade glioma treatment remains complex. While radiation plus chemotherapy (PCV) offers the best survival, research continues on less toxic options like temozolomide to balance efficacy and long-term cognitive health.
Area of Science:
- Neuro-oncology
- Molecular Diagnostics
- Clinical Trials
Background:
- Low-grade gliomas pose management challenges due to long survival and treatment toxicity concerns.
- Tumor rarity complicates clinical trial design for optimal care strategies.
Purpose of the Study:
- To review current management issues and recent advances in low-grade glioma treatment.
- To evaluate the role of surgery, radiation, and chemotherapy in optimizing patient outcomes.
- To address the impact of isocitrate dehydrogenase (IDH) mutations on diagnosis and prognosis.
Main Methods:
- Review of current literature and clinical trial data on low-grade glioma management.
- Analysis of diagnostic advancements, including IDH mutation status.
- Evaluation of treatment strategies: maximal safe debulking, radiation therapy, and chemotherapy (PCV, temozolomide).
Main Results:
- IDH mutations improve diagnosis and risk stratification for low-grade gliomas.
- Maximal safe tumor debulking is increasingly supported as a first-line approach.
- Combined radiation and PCV chemotherapy demonstrated a significant survival advantage over radiation alone.
- Chemotherapy showed comparable effectiveness to radiation for a specific molecular subtype, but overall survival data favor combination therapy.
Conclusions:
- The combination of radiation and PCV chemotherapy provides the most robust survival benefit for low-grade gliomas.
- Further research is needed to assess temozolomide's efficacy compared to PCV with radiation.
- Investigating initial chemotherapy to defer radiation-induced cognitive toxicity while maintaining survival is a key future direction.
